The highest impact factor is 508.7 the clinical research of CISPOLY Biomethylation has been listed in CA-A Cancer Journal for Clinicians

Methylation is an important epigenetic modification that has a significant impact on gene expression and cellular function. It plays an important role in the occurrence and development of various diseases such as cancer, neurological disorders, and cardiovascular diseases. According to statistics, more than 30 DNA methylation based detection methods have been launched globally, and in recent years, they have developed rapidly in China. Their clinical applications mainly include auxiliary diagnosis of cancers such as cervical cancer, colorectal cancer, lung cancer, and urothelial carcinoma.

Since its establishment in 2020, CISPOLY has focused on the development and application of gynecological tumor methylation detection, and actively carried out multiple retrospective and prospective multicenter research clinical trials. It has spoken out and shared in numerous international and domestic academic events such as EUROIN, ESGO, ASGO, ASCCP, CSCCP, and has been published or published in multiple authoritative academic journals.

Among the numerous honorary achievements, CISPOLY's methylation based multicenter queue project for early screening and diagnosis of endometrial cancer was published in the international "divine journal" CA-A Cancer Journal for Clinicians, becoming the first domestically recognized enterprise in the field of gynecological oncology with methylation detection. In addition, three clinical studies on endometrial cancer methylation and cervical cancer methylation jointly conducted by CISPOLY and Beijing Union Medical College Hospital are also prominent, representing that CISPOLY methylation detection can become one of the most advanced applications in clinical practice.

The CA-A Cancer Journal for Clinicians (abbreviated as CA-Cancer J Clin) was founded in 1950 and is a comprehensive, peer-reviewed academic journal sponsored by the American Cancer Society. It is its flagship journal and covers topics related to cancer diagnosis, treatment, and prevention. The latest JCR impact factor is 244.585, which even reached 508.702 in 2020, ranking first among all journals and far higher than internationally renowned journals such as Cell (41.582), Nature (49.962), and Science (47.728).

The publication of clinical research on CISPOLY Methylation Detection in CA Cancer J Clin is a strong recognition of its innovative technology and application, which will further promote the widespread recognition of related products in clinical practice. At present, CISPOLY's cervical cancer methylation detection product, CISCER ® Has obtained NMPA Class III certification and has been successfully applied in hundreds of tertiary hospitals; Methylation detection product for intrauterine cancer -CISENDO ® We are actively registering, and other research and product development are also being rapidly promoted. In the future, CISPOLY will continue to deepen its research and clinical application in gynecological tumor methylation detection, contributing to women's health.

About CISPOLY

Beijing Origin Poly Bio-Tec Co., Ltd(CISPOLY). is a technology enterprise driven by innovative technology and with a focus on health. CISPOLY is a pioneer in the field of early diagnosis of gynecological tumors. With exclusive technology and patented biomarkers as the core, it has developed early diagnosis products for gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, filling the gap in this field.

As women's attention to their own health becomes increasingly close, the women's health market will have great potential. In addition to the early screening and diagnosis product line for gynecological tumors, CISPOLY will also establish more product pipelines related to women's health in the future, creating a leading enterprise in technological innovation in the women's health market.